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Host susceptibility to severe influenza A
virus infection
Sara Clohisey1 and John Kenneth Baillie1,2*
Abstract
Most people exposed to a new flu virus do not notice any symptoms. A small minority develops critical illness. Some of
this extremely broad variation in susceptibility is explained by the size of the initial inoculum or the influenza exposure
history of the individual; some is explained by generic host factors, such as frailty, that decrease resilience following any
systemic insult. Some demographic factors (pregnancy, obesity, and advanced age) appear to confer a more specific
susceptibility to severe illness following infection with influenza viruses. As with other infectious diseases, a substantial
component of susceptibility is determined by host genetics. Several genetic susceptibility variants have now been
reported with varying levels of evidence. Susceptible hosts may have impaired intracellular controls of viral replication
(e.g. IFITM3, TMPRS22 variants), defective interferon responses (e.g. GLDC, IRF7/9 variants), or defects in cell-mediated
immunity with increased baseline levels of systemic inflammation (obesity, pregnancy, advanced age). These
mechanisms may explain the prolonged viral replication reported in critically ill patients with influenza: patients with
life-threatening disease are, by definition, abnormal hosts. Understanding these molecular mechanisms of susceptibility
may in the future enable the design of host-directed therapies to promote resilience.
Keywords: Influenza, ARDS, Susceptibility, Genetics
Introduction
The normal response to infection with influenza A virus
(IAV) is to remain asymptomatic. During the 2009/2010
pandemic, serosurveillance studies revealed that a major-
ity of volunteers who tested positive for antibodies to
the new H1N1pdm09 virus did not report any symptoms
[1]. The majority of people newly exposed to one of the
most dangerous viruses to circulate in human popula-
tions in recent history, which in the same population
created an overwhelming burden of critical illness [2],
did not notice any symptoms.
Wide variation in susceptibility is a general feature of
human and animal populations exposed to any pathogen
[3]. Explaining the mechanisms of susceptibility may
enable effective targeting of vaccine therapies, may
reveal new therapeutic approaches [4, 5], and, in theory,
may contribute to future clinical risk prediction models.
Variation attributable to the virus
Initial exposure
As with any infectious disease in a given host, the site of
infection, the scale of the initial exposure, and the
virulence, degree of pathogenicity, of the pathogen
determine the nature of the disease in IAV infection.
Although the alimentary tract is a common site of infec-
tion in other species (for example the natural hosts,
water fowl [6]), initial infection in humans is through
the respiratory tract. The number of viable IAV virions
transmitted has a direct effect on the probability of
symptoms, both in animal models [7] and human
challenge studies [8]. This may explain a proportion of
the variation in individual responses to the virus.
Virulence
The virulence of the virus itself varies greatly. Perhaps
fortunately, there is a general trend for the most virulent
IAV strains to be less transmissible; that is, those that
cause the most severe disease are less likely to be passed
on to others. While highly transmissible IAV strains,
such as H1N1pdm09, replicate well in the upper
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respiratory tract, viruses associated with higher rates of
severe disease, such as H5N1 and H7N9 avian IAV, ex-
hibit tropism for the lower respiratory tract [9, 10].
Within a given strain, not all IAV viruses are the same.
In fact, it is statistically unlikely that any two IAV virus
particles will have exactly the same genome sequence.
Small changes, such as a single amino acid change in the
hemagglutinin protein, can significantly alter the tropism
of the virus for example, increasing the likelihood of
spread to the lower respiratory tract and establishing a
more severe infection [11].
IAV viruses change rapidly by two mechanisms: shift
and drift. Shift is the exchange of viral segments between
strains, occasionally resulting in a new IAV subtype to
which a large proportion of the population does not
have existing immunity. This shuffling of the viral genes
contributes to the sudden and dramatic change in viru-
lence that may occur from season to season, and to zoo-
noses, as IAV jumps from its natural avian host to
mammalian pig and human hosts.
Drift refers the accumulation of small mutations in the
viral genome that occur on a continuum. Because of the
short genome (around 13,500 bases of RNA are carried
by a functional virion particle) and a very high error rate
when this genome is replicated [12, 13], viral quasispe-
cies arise, leading to a heterogenous swarm of virions
[14]. This variation enables IAV to evolve extremely
rapidly where a selective pressure exists. For example, it
is likely that IAV can evolve de novo resistance to antivi-
rals during treatment of a single patient [15–17].
Studies of viral whole genome sequence during out-
breaks have failed to identify consistent viral factors
associated with severe disease [18]. It is therefore likely
that viral factors do not explain the vast spectrum of
variation observed in the disease.
Variation attributable to the host
Previous exposure to IAV
Due to the remarkable memory of the adaptive and innate
immune systems, previous exposure to IAV has a strong
effect on future susceptibility. Adaptive immune memory
is highly strain-specific and provides targeted antibody-
mediated defence against IAV [19].
The first IAV strain to which a child is exposed has a
profound effect on subsequent immunity—a concept
known as original antigenic sin [20]. The host immune sys-
tem is extensively programmed by this first IAV exposure,
such that the susceptibility of whole populations of adults
can be predicted using the patterns of circulating IAV in
each patient’s year of birth [21]. This has been proposed as
one reason why the burden of mortality for the 2009/2010
outbreak was shifted towards patients younger than 65
years of age [22]—patients over 65 years old are more likely
to have been exposed at a young age to an IAV strain simi-
lar to the H1N1pdm09 strain, and were hence protected.
Interestingly, the lifelong immunity provided by this
first IAV exposure has broad protective effects against
different IAV strains [21]. Cell-mediated immunity may
play an important role in this protection. An IAV
challenge study in healthy volunteers found that pre-
existing CD4(+) T cell responses to IAV nucleoprotein
and matrix proteins were present prior to infection [23].
The magnitude of this CD4(+) T cell response when
challenged correlated with reduced symptoms and
reduced virus shedding.
Host demographics
Regardless of prior exposure, the most reliably quantified
risk factors for life-threatening seasonal and pandemic
IAV are advanced age (> 65 years), obesity, immunosup-
pression, cardiovascular disease, and neuromuscular
disease [24]. A number of well-recognised host factors—
best summarised by the broadly understood but poorly
defined term, “physiological reserve”—increase the
chance of organ failure and death following any severe
injury or infection. These factors are extensively dis-
cussed elsewhere in the critical care literature; here, we
focus on host factors that are thought to confer some
element of specific susceptibility to IAV (Fig. 1).
Pregnancy
Studies dating back to the 1918–1919 pandemic have sug-
gested that pregnancy, particularly in the third trimester,
increases the risk of death from IAV [25]. Additionally,
pregnant women have a higher rate of hospitalisation with
seasonal IAV [26]. However, in the largest systematic
review of clinical risk factors for IAV, pregnancy was not
Fig. 1 Conceptual visualisation of variation in specificity of host
susceptibility factors. Factors predicted to confer more specific
susceptibility to influenza are placed higher in the diagram
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independently associated with severe disease from either
seasonal or pandemic IAV [24].
The immunological changes that occur in pregnancy
are theoretically compatible with increased severity of
IAV: in particular, an increase in innate immune activa-
tion and a decrease in the number and activity of cells
associated with cytotoxic immunity—in which infected
cells are killed to limit the dissemination of the virus
[27]. These changes may lead to an increased propensity
to develop ARDS [28] and a decreased ability to elimin-
ate IAV-infected cells, which is a core component of
anti-IAV immunity.
Some indices of severity used in epidemiological stud-
ies are themselves directly affected by pregnancy. The
cardiovascular adaptations to pregnancy, combined with
an increased metabolic rate, a decrease in functional
residual capacity, and increased basal ventilation to per-
fusion mismatch, are expected to worsen hypoxaemic
respiratory failure following any insult. In parallel,
admission to hospital or critical care may be in part
biased by elevated concern for a pregnant patient, and
by the perception of high risk of severe IAV [29].
Obesity
Obesity was identified as a risk factor for IAV infec-
tion over a decade ago and confirmed during the
swine flu pandemic [30, 31] when it was associated
with an increased risk of death [32]. Although comor-
bidities associated with obesity—specifically diabetes
mellitus and cardiovascular disease—compromise pul-
monary host defence and increase the chance of
death following any severe systemic injury [33], an in-
dependent association between obesity and severe
IAV is robust and replicated [24].
In parallel with the immune changes associated with
pregnancy, obese patients are more likely to have
impaired cell-mediated immunity and excessive chronic
activation of the innate immune system [34]. This is
reflected in a study which demonstrated that among
vaccinated adults, those who are obese are more likely to
suffer severe consequences of IAV [35]. Furthermore, it
has been shown that obese adults have an impaired
antibody response to IAV vaccination [36], and impaired
CD4(+) and CD8(+) T cell responses IAV in vitro [37].
Obese patients have a prolonged period of viral repli-
cation and shedding, even in the absence of clinical
disease [33].
Age
Extremes of age are well-recognised risk factors for severe
disease. Children under the age of 5 years, and particularly
those under 2 years, have consistently been found to be at
high risk for severe disease and serious complications fol-
lowing IAV infection [38–40]. Functional immaturity of
the immune system, together with a failure to recognise
IAV-related antigens, may largely explain this effect.
In industrialised countries, the group at highest risk of
death from seasonal IAV is those over 65 years of age
[22, 41, 42]. Senescence affects antiviral immunity in
complex ways; it is difficult in clinical epidemiological
studies to distinguish the effect of these immune
changes from the effects of frailty and antigenic expos-
ure. Baseline markers of systemic inflammation are ele-
vated [43] and circulating T cell counts are reduced.
Naive T cells, a key component of cell-mediated adaptive
immunity, are lost from the circulation due to the
process of thymic involution, which begins very early in
life [44]. In mouse models of IAV infection, aged mice
exhibit slower antiviral and adaptive immune responses,
and more severe disease [45].
Expansion of clonal T cell populations, driven by cyto-
megalovirus (CMV), occurs in older adults and may im-
pair T cell responses to new pathogens [46]. In contrast,
in the young, a multi-omic systems analysis demon-
strated that CMV infection is associated with an
enhanced T cell mediated response to IAV vaccination
[47]. Integrating systems studies of host response to IAV
infection with markers for genetic susceptibility (see
below) may in the future reveal new biological pathways
and patterns of disease [48].
As with pregnancy and obesity, ageing is associated
with both an increase in the basal activation of the in-
nate immune system (sometimes referred to as “inflam-
maging”) and a decrease in cell-mediated immunity.
This combination of mechanisms may explain the par-
ticularly strong effects on susceptibility.
Host genetics
Susceptibility to death from any infection is strongly
inherited by children from their parents [49]. In IAV,
numerous genetic studies in humans and animal models
have revealed specific genes associated with susceptibil-
ity, which are extensively reviewed elsewhere [50–52]. In
addition to the specific genetic variants discussed below,
there is direct evidence, from a study of death records in
Utah, that susceptibility to IAV is heritable at a popula-
tion level [53].
Inborn errors of immunity
Much of what is known about human genes associated
with IAV susceptibility has been discovered from loss-
of-function mutations in the immune system, which lead
to loss of the gene product or a substantial reduction in
gene function. These often lead to severe defects that
are likely to present in childhood. Such variants can
reveal key components of the immune response to a spe-
cific infection. In considering the biological lessons from
such discoveries, it is important to consider that, in most
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people, these components of the immune system func-
tion perfectly well and may not be suitable targets for
therapy. Secondly, there is little that can be inferred
from the absence of any particular gene, or immune
process, from the list of loss-of-function defects associ-
ated with susceptibility to IAV.
The conditions that must be met for such a gene to be
discovered are not restricted to disease susceptibility.
Many variants that confer susceptibility to IAV have
broader pleiotropic effects that may be terminal in utero
or in early life, or may lead to susceptibility to other in-
fections or autoimmune conditions that obscure the
clinical picture. Alternatively, some variants may lead to
strain-specific susceptibility and will only be detected
following exposure to the right virus.
The full range of genetic defects associated with sus-
ceptibility to IAV in animal models is reviewed else-
where [54, 55]. So far, three known human genes, all
transcription factors active primarily in myeloid cells,
have been found to have loss-of-function variants that
increase susceptibility to IAV. Since transcription factors
function as master regulators of large numbers of genes,
functional deficiencies are expected to have broad, non-
specific effects.
IRF7
In 2015, Ciancanelli et al. identified a patient with a mu-
tation in the transcription factor Interferon regulatory
factor 7 (IRF7) that led to severe infection and ARDS
when she was 2.5 years old [56]. IRF7 is a transcription
factor and a key regulator of the type I interferon re-
sponse. This was the first published example of a single-
gene inborn error of immunity that was specific to IAV.
Both parents were heterozygous for different loss-of-
function alleles, but each had sufficient functional IRF7
activity allowing them to avoid severe IAV. The patient
inherited these two different loss-of-function alleles
(compound heterozygosity) leading to complete loss of
functional IRF7. Leukocytes and plasmacytoid dendritic
cells from this patient produced very little interferon
type I (α/β) and III (γ) in vitro indicating that expression
and production of these interferons in these cell types is
specifically IRF7-dependent in IAV infection in humans.
IRF9
Whole exome sequencing of 20 children identified a
variant in the gene encoding interferon regulatory factor
9 (IRF9) in a 2-year-old child who had previously
suffered from bronchitis and biliary perforation [57].
The child inherited a mutation on both alleles from con-
sanguineous parents leading to a single change in the
DNA sequence (single nucleotide polymorphism, SNP)
in the IRF9 gene. This SNP occurs at an essential site
leading to aberrant processing of the gene transcript and
thus the expression of a truncated, functionally defective,
protein product.
In this case, IRF9 was only partially defective. Activation
of interferon-stimulated gene 3 (ISG 3) was impaired in
response to IAV infection or interferon α stimulation, but
other IRF9-dependent pathways remained intact. The
consequence of this appears to be a global reduction in
type I interferon responses, a key mechanism of early mu-
cosal resistance to infection, in all cell types. Unrestricted
viral replication was observed in cells from the patient and
was also shown for parainfluenza virus and respiratory
syncytial virus.
GATA2
GATA2 is a zinc finger transcription factor, part of the
GATA family, so named because they bind a G-A-T-A
pattern (also called a motif) in DNA sequence. Tran-
scription factor binding at sites bearing this motif alters
the probability that a given gene will be transcribed, and
ultimately controls the amount of the encoded protein
that is made. GATA2 deficiency results in primary im-
mune cell deficiency and affects a wide range of cell
types. Decreased circulating counts of B lymphocytes,
NK cells, monocytes and plasmacytoid dendritic cells
have been observed, along with reduced T cell thymic
output. In 2018, Sologuren et al. published a case study
of a father and son who contracted and subsequently
died from severe IAV [58]. Both patients were heterozy-
gous for a novel mutation in GATA2 that led to a
dysfunctional protein.
Despite the known effects of GATA2 deficiency on
primary immune development, the first, older patient
had suffered few health problems prior to his 30th year,
after which frequent respiratory illnesses and a single
incidence of viral pneumonia is reported prior to his
severe illness. The second patient had been hospitalised
with pneumonia at 16 without recurrence until hospi-
talisation with severe IAV at 31. The authors attribute
protection from viral and bacterial infection observed
in the lifetime of these patients to long-living memory
T and B cells.
Population genetic studies
Genetic variants with less drastic effects on susceptibility
can be detected by comparing flu-susceptible popula-
tions with control populations (Table 1). These studies
generally look for candidate genes or take a genome-
wide approach.
Candidate gene association studies have a long but
troubled history in human genetics. Genes are selected
because of some underlying hypothesis; single variants
within these genes are then chosen because they are
believed to have an effect on the expression or function
of the gene. Genotype frequencies (that is, the
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proportion of a population who have a given variant) at
these genomic positions are then compared between a
case and control group. This has the advantage of econ-
omy, since only one or two variants need to be geno-
typed for each participant, and has the superficial
appearance of statistical efficiency, since fewer compari-
sons are made.
The fundamental limitation is that, in a human gen-
ome composed of 3 × 109 bases, of which 4 − 5 × 106 are
different between any random pair of people [59], the
probability of choosing the right base is very low. In the
event that a given variant meets a nominal level of
significance, the evidence for an association is easily
misinterpreted. Looking backwards from a single small
p value, it is common to focus on the fact that probabil-
ity of seeing such an association by chance alone is very
low. What is easy to forget is that the probability of such
an association existing is also very low.
An understanding of this methodology is important
for the interpretation of such studies. Many of the posi-
tive studies reflect more the biases of well-informed in-
vestigators in the choice of target genes. The additional
value of an unreplicated genetic association on this
background is often small.
Table 1 Genes and associated single nucleotide polymorphisms (SNPs) related to influenza A susceptibility in humans
Gene Gene name Function SNP Reference
Entry factors/cell membrane
IFITM3 Interferon-induced transmembrane
protein 3
Antiviral rs12252-C [64–66]
rs34481144-A [67]
CD55 Complement decay-accelerating
factor precursor 55
Inhibition of complement
activation
rs2564978 T/T [71, 72]
TMPRSS2 Transmembrane protease, serine 2 Serine protease rs2070788 GG [73–76]
GLDC Glycine decarboxylase Component of the glycine
cleavage
system
rs1755609-G [80]
LGALS1 Galectin-1 Cell-cell interactions rs4820294 [82]
rs2899292 [82]
rs4820294 [82]
ST3GAL1 (*) ST3 beta-galactoside alpha-2,
3-sialyltransferase 1
Transfer of sialic acids to
galactose-containing substrates
rs113350588 [90]
rs1048479 [90]
TNFA (*) Tumour necrosis factor alpha Inflammation and immune
signalling
rs361525-A [91]
TLR3 (*) Toll-like Receptor 3 Pathogen recognition rs5743313-CT [92]
rs5743313-CC [72]
Surfactant proteins
SP-A2 (*) Pulmonary-surfactant associated
protein A2
Pathogen binding and immune
signalling
rs1965708-C [89]
rs1059046-A [89]
SP-B Pulmonary-surfactant associated
protein B
Pathogen binding and immune
signalling
rs1130866 [77]
Interleukins
IL1A (*) Interleukin 1 alpha Inflammation and immune
signalling
rs17561-T [84]
IL1B (*) Interleukin 1 beta Inflammation and immune
signalling
rs1143627-C [84]
rs16944-AG [85]
rs3136558-TC [85]
IL28B Interleukin 28 b, IFN-λ 3 Immunomodulation rs8099917-TT [86]
IL17 (*) Interleukin 17 Inflammation and immune
signalling
rs2275913
(GG and AG)
[87]
IL6 (*) Interleukin 6 Inflammation and immune
signalling
rs1818879-
(GA and GG)
[85, 88]
Gene: gene symbol. Gene name: gene name and alternate name. Function: summary function of gene product. SNP: SNPs associated with host susceptibility to
influenza A associated with gene. (*) represents genes not addressed in the text
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Nonetheless, candidate gene approaches in various forms
detected numerous real and informative associations with
disease before the advent of genome-wide genotyping tech-
nology [60]. We focus here on larger studies, those that
have been replicated, and studies with particular relevance
to the pathogenesis of severe IAV.
Genome-wide approaches seek to eliminate the afore-
mentioned bias. In the most widely used design, the
genome-wide association study (GWAS), hundreds of
thousands of common variants are genotyped in each
patient. This is expensive and requires correction for
multiple comparisons. A widely used convention is to
correct for 1 × 106 independent comparisons in each
study, requiring a p value <5 × 10−8 for significance.
Large numbers of patients are needed to detect associa-
tions at this level above the background noise of vari-
ation in human populations. However, genome-wide
approaches use no preconceptions about the pathogen-
esis of disease. Hence, such methods have the potential
to teach us something that we did not already know. Be-
cause of the stringent threshold for statistical significance,
and the burden of multiple testing, statistical power to
detect small effects is usually lacking unless many tens of
thousands of patients are included. For this reason, the
expected outcome is false-negatives. Hence, we would
caution against drawing any conclusion from the absence
of significant associations within a given gene.
Genome-wide in vitro knockdown screens can also be
used to limit bias and enable genome-wide discovery. In
this approach, although a candidate gene is often
selected from cell culture results and tested for genetic
associations in patients, there is an important difference
from single-gene candidate studies: the pool of genes
from which the candidate is chosen comprises the entire
protein-coding part of the genome.
Intracellular antiviral immunity IFITM3
A role for interferon-induced transmembrane protein 3
(IFITM3) in IAV replication was discovered in an in
vitro genome-wide knockdown screen in cultured cells
[61]. The protein product of this gene restricts IAV
entry by blocking the fusion of host and viral mem-
branes [62] and acts as a restriction factor in viral infec-
tions, along with family members IFITM1 and IFITM2
[61]. IFITM proteins were also shown to inhibit the early
replication of other virus types, for example the West
Nile Virus [63].
Based on this genome-wide knockdown screen, a can-
didate gene sequencing approach was conducted to test
for an association with severe illness. The 2009/2010
pandemic provided a colossal natural experiment—a
large proportion of the population were exposed to a
new pathogen, but only a small minority developed life-
threatening illness requiring critical care. Focusing on
these previously healthy adults with life-threatening IAV
(in the GenISIS and MOSAIC studies) may have in-
creased the effect size seen [64].
Genotypes at every variant within the IFITM3 gene
were compared with population controls, identifying a
single variant (rs12252-C) associated with severe IAV.
This variant is rare in the European cohorts in which it
was discovered, but is frequent in the Han Chinese co-
horts hospitalised with severe H1N1pdm09 infection
[65]. The association has been replicated in independent
studies in different populations [66].
A second SNP associated has been shown in population-
level studies to regulate IFITM3 expression. rs34481144-A
encourages the transcription factor CTCF to bind to the
regulatory region of IFITM3 and repress gene expression
in response to IAV infection [67]. This SNP can also dis-
rupt the methylation pattern (a key modification of DNA
that usually silences genes) in the regulatory region leading
to cell type-specific effects. IFITM3 expression in memory
CD8(+) T cells in response to viral infection has been
found to protect and encourage survival of these cells
allowing for the establishment of adaptive immunity. Loss
of methylation at this site prevents CTCF from binding to
the DNA and inducing expression of IFITM3 in response
to the pathogen, thus reducing cell survival. This is esti-
mated to lead to a 2.6-fold increased risk of a severe out-
come upon IAV virus infection. IFITM3 has also been
recently shown to have a protective effect on the heart dur-
ing severe IAV infection. Myocarditis has been associated
with IAV infection since the 1918 pandemic [68], and IAV
has been shown to lead to a sixfold increased risk of myo-
cardial infarction in the 7 days post infection [69]. So far,
IFITM3 is the only gene for which SNPs have been identi-
fied and independently confirmed in vivo and in vitro to
restrict IAV replication [70]. However, this gene is not spe-
cific to IAV replication and the full extent of the antiviral
actions remains to be discovered.
Immune-myeloid/T cell CD55 decay accelerating factor
Unbound complement is rapidly inactivated in plasma.
Where this process is defective, uncontrolled comple-
ment activation can damage host cells.
CD55 prevents the formation and accelerates the decay
of C3 and C5 convertases. These proteases are part of the
complement system and have roles in opsonisation and
the release of inflammatory molecules. CD55 polymor-
phisms were associated with severe H1N1pdm09 infection
(defined as requiring supplementary oxygen, admission to
intensive care or death) [71]. This study found carriers of
the rs2564978-T/T polymorphism had significantly lower
levels of surface CD55 on their circulating monocytes
compared to the more common C allele. Further work
identified a deletion in a nearby regulatory region as the
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element responsible for the specific effect on both protein
and mRNA levels of CD55 in monocytes. A more recent
study of Han Chinese individuals that looked at several
genes confirmed an association between CD55 rs2564978
T/T and death from severe IAV infection [72].
The cumulative effects of multiple SNPs (IFITM3,
CD55, and the immune cell receptors TLR3 and TLR4)
on IAV susceptibility have been examined in a targeted
study [72]. This independently confirmed the association
of the CD55 rs2564978 polymorphism with severity, and
the IFITM3 rs12252-C and TLR3 rs5743313-CC geno-
types were both over represented in fatal cases.
TMPRS22
In a small-scale pilot study, genome-wide genotypes of
42 patients with severe IAV were compared to 42 con-
trols with mild IAV. The rs2070788-G allele of
TMPRS22 was significantly overrepresented in severe
compared with mild cases of H1N1pdm09, with a > 2-
fold higher risk of severe infection. There was higher
TMPRS22 expression in human lung tissues with the
high-risk GG genotype [73]. This was replicated in a tar-
geted study of 162 severe and 247 mild IAV patients.
This genetic association in humans is highly biologically
plausible: TMPRS22 has been shown to play a role in
haemagluttinin cleavage, an important step in IAV repli-
cation. Additionally, mice lacking this gene are strongly
protected from IAV infection [74–76].
SP-B
This genome-wide array also identified a SNP in
pulmonary-surfactant-associated protein B (SP-B),
rs1130866, as a potential association. This SNP was
genotyped in a targeted study of 111 severe and 185
mild IAV patients to replicate the finding [77]. Again,
this is a plausible association with severe disease: SP-
B forms a key part of pulmonary surfactant and is
essential for lung function. A subset of the same pro-
tein family, SP-A and SP-D, have been shown to initi-
ate and enhance immune cell ingestion and killing
(opsonisation) of pathogens and play a role in the
progression of IAV in mice [78]. A polymorphism
associated with SP-B, rs1130866 [77], has also been
associated with COPD in several cohorts [79].
GLDC
Susceptibility to severe H1N1 infection was analysed in a
recent genome-wide study (integrated with data on gen-
etic variants associated with altered gene expression)
which implicated an intronic SNP of GLDC, rs1755609-G
[80]. The GLDC gene encodes glycine decarboxylase, also
known as the P protein of the glycine cleavage system, a
pathway in glycine metabolism [81]. The association was
replicated by targeted genotyping in a larger cohort of 174
patients suffering severe IAV infection and 258 mildly in-
fected controls. The risk variant corresponds to higher
GLDC expression in lymphoblastoid cell lines and human
lung tissues. Consistent with this effect, inhibition of
GLDC in cultured bronchial epithelium using siRNA or a
specific inhibitor, aminooxyacetic acid (AOAA), leads to
an increased type I IFN response and a restriction of viral
replication in vitro. This effect on viral restriction was
seen with both H1N1 and H7N9, and the allele genotype
was replicated in susceptibility cohorts for both viruses.
The protective effect of AOAA against H1N1 was shown
in mice to be comparable with that of zanamivir.
Galectin-1
Susceptibility to severe H7N9 was examined in a GWAS
performed with 102 patients and 106 controls who
worked with poultry. This study identified rs13057866,
associated with Galectin-1 (LGALS1), as a potential sus-
ceptibility factor. LGALS1 is a lectin that may have a
role in modulating cell-cell and cell-matrix interactions.
The study further demonstrated that genetic variants of
LGALS1, including rs4820294 and rs13057866, lead to
higher expression of LGALS1 protein in human cells,
possibly leading to a protective effect. Carriers of the
rs4820294/rs2899292 GG haplotype were found to have
higher LGALS1 protein in lymphoblastoid cells and ex-
pression levels of LGALS1 in human lung correlated
with the rs4820294 SNP [82].
Conclusions
The role of host factors in susceptibility suggests a clin-
ically important conclusion: there is something unusual
about the small minority of patients who develop critical
illness following IAV. Therefore, extrapolating from
human challenge and primary care studies of viral clear-
ance is very likely to lead to error. Viral clearance among
critically ill patients is slow and incomplete [83]. Hence,
the critically ill population should be regarded—by
definition—as highly abnormal hosts.
Susceptible hosts may have impaired intracellular con-
trols of viral replication (e.g. IFITM3, TMPRS22 variants),
defective interferon responses (e.g. GLDC, IRF7/9 vari-
ants), or defects in cell-mediated immunity with increased
baseline levels of systemic inflammation (obesity, preg-
nancy, advanced age). In the context of any of these sus-
ceptibility mechanisms, failure to clear the virus is an
expected consequence, indicating that a full course of ef-
fective antiviral therapy is likely to benefit this population.
In the future, understanding the biological mechanisms of
susceptibility to severe IAV may yield therapeutic targets
to modify the biology of the susceptible hosts in critical
care and render them resilient.
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